NCT05753436CompletedPhase 2
Curcumin's Effect on Diabetic Patients With Atherosclerotic Cardiovascular Risk
Evaluation of the Effect of Curcumin Administration on the Clinical Outcome of Diabetic Patients With Atherosclerotic Cardiovascular Risk
Source: ClinicalTrials.gov · Last updated 22 Aug 2025
Brief summary (registry, in English)
The aim of the study is to assess the safety and efficacy of Curcumin supplementation in combination to the conventional therapy in improving the clinical outcomes, oxidative stress and inflammation in diabetic patients with risk of ASCVD.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 72 (actual)
- First submitted
- 31 Jan 2023
- Start date
- 1 Jul 2023
- Primary completion date
- 1 Jan 2024
- Lead sponsor
- Ain Shams University
- Diseases
- High blood pressure, Type 2 diabetes
- NCT number
- NCT05753436
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 72
- From 1 Jul 2023 to the primary completion date, 1 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Congenital or acquired bleeding disorders.
- Cholelithiasis, gall bladder or biliary tract disease or other active liver diseases.
- Oral hypoglycemic drugs that affect cardiovascular diseases risk.
- Patients with clinical ASCVD (myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease).
Other
- Pregnant or breastfeeding women.
Who the study is looking for
- Adult Male or female patients aged 40 years or older
- A calculated 10 year ASCVD risk score of 5 % or more
- Patient previously or newly diagnosed with hypertension
- Patient previously or newly diagnosed with dyslipidaemia
- Patients diagnosed as Type 2 diabetes mellitus taking insulin or oral hypoglycemic agent with controlled HbA1c \< 10%
- Willingness and ability to give informed consent.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Demerdash Hospital, Faculty of Medicine, Ain Shams University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.